Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity,

[keangkong]

Innovent Biologics (Nov. 19, 2025). Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints. PRNewswire, https://www.prnewswire.com/news-rel...nd-all-key-secondary-endpoints-302620471.html.

Highlights include:

Innovent plans to ask the Chinese version of the FDA to approve a new maximum dosage of 9 mg per week. Currently, the maximum recommended dosage is 6 mg per week.

"Among participants (without type 2 diabetes) with baseline liver fat content ≥10%, the mean percent change in liver fat content from baseline to week 60 was -71.9% in the mazdutide 9 mg group compared with 5.1% in the placebo group." I believe the figure for tirzepatide is an 8% reduction. In other words, GIPR agonism appears necessary in order to dramatically reduce liver fat.

"[A]mong participants without type 2 diabetes, the mazdutide 9 mg group showed a mean weight reduction of 20.08% at Week 60 (placebo: 2.81%) . . ."

"During the treatment period, participants in the mazdutide group exhibited continuous weight loss, with no plateau observed in Week 60."

We just have a press release right now. Eventually we'll get a scholarly article. Perhaps there will a "poster presentation" at an academic conference beforehand.

 

[keangkong]

In contrast, retatrutide obtained a 24% weight loss at 48 weeks (Jastreboff, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New Eng. J. Med., 389(6), 514–526, https://www.nejm.org/doi/full/10.1056/NEJMoa2301972), 12 weeks less than the 60 weeks studied int he mazdutide study. In the retatrutide study, the 24% represents the percent weight excluding the weight loss on placebo. The closest comparable figure in the mazdutide study is 17%. Still maz's performance is quite impressive.

 

[IshimaruKenta]

I could have sworn I saw that mazdutide went up to 16mg in trials. 🤔

 

[PopTart]

I could have sworn I saw that mazdutide went up to 16mg in trials. 🤔

It was in Phase 1 clinical trial (NCT05623839)

 

[IshimaruKenta]

It was in Phase 1 clinical trial (NCT05623839)

Oh cool, I knew I had seen it before. Thank you.

 

[keangkong]

It was in Phase 1 clinical trial (NCT05623839)

Sixteen milligrams has been tested in a phase one trial and a phase two trial. The phase one trial results have been published in a peer-reviewed journal. The phase two trial results have not yet been published in a journal, however, they were presented in a poster presentation at the recent Obesity Week conference.

While taking a high dose of a GLP-1 drug often results in a greater weight loss, higher doses yield particularly impressive results with mazdutide.

Phase 2 trial: Hsia, et al. (Poster - Obesity Week 2025). Mazdutide (LY3305677) in Participants With Obesity or Overweight - A Phase 2 Dose-Finding Study. See also Hsia, et al. (2025). Mazdutide (LY3305677) in participants with obesity or overweight - a phase 2 dose-finding study. Abstract Oral-104; Monostra (Nov. 18, 2025). GLP-1-glucagon dual agonist reduces weight across three dosing regimens in obesity. Endocrine Today.

Phase 1 trial: Bhattachar, et al. (2025). Mazdutide reduces body weight in adults with overweight or obesity - A high-dose Phase 1 trial. Diabetes Obesity & Metabolism 27(11), 6460-6469.

It looks to me like both of the trials involving 16 milligram doses were run by Eli Lilly, not Innovent Biologics, the licensed manufacturer and distributor in China.